Tyme Technologies, Inc. (NASDAQ:TYME) is an emerging biotechnology company developing Cancer Metabolism-Based Therapies (CMBTs) that are intended to be effective across various solid tumors and hematologic cancers, while having low toxicity profile. The company’s therapy is designed to compromise the cancer cell’s innate metabolic weaknesses, resulting in cell death through oxidative stress and exposure to the body’s natural immune system. The mechanism of action of CMBT is naturally more effective and safer than other therapies.
The company’s lead candidates, SM-88 (racemetyrosine) and TYME-18, are first-in-class CMBT compounds. Early clinical results from trials of SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, demonstrate the potential of the company’s CMBT pipeline, offering a new option for long-term management of advanced cancers.
(Image source: company website)
The company’s lead candidate at an advanced stage is SM-88, “an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the